Virax Biolabs Group (Virax Biolabs Group) Revenue per Share

: $0.44 (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

Virax Biolabs Group's revenue per share for the six months ended in Sep. 2023 was $0.43. Virax Biolabs Group's revenue per share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.44.

Warning Sign:

Virax Biolabs Group Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Virax Biolabs Group was 2800.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -64.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Virax Biolabs Group's Revenue per Share or its related term are showing as below:

VRAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -64.3 Med: -64.3 Max: -64.3
Current: -64.3

During the past 4 years, Virax Biolabs Group's highest 3-Year average Revenue Per Share Growth Rate was -64.30% per year. The lowest was -64.30% per year. And the median was -64.30% per year.

VRAX's 3-Year Revenue Growth Rate is ranked worse than
95.83% of 768 companies
in the Biotechnology industry
Industry Median: 5.35 vs VRAX: -64.30

Virax Biolabs Group Revenue per Share Historical Data

The historical data trend for Virax Biolabs Group's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Revenue per Share

0.09

0.11

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Revenue per Share	Get a 7-Day Free Trial			-	-	0.02	-	0.43

Competitive Comparison

For the Biotechnology subindustry, Virax Biolabs Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's PS Ratio distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's PS Ratio falls into.

Virax Biolabs Group Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Virax Biolabs Group's Revenue Per Share for the fiscal year that ended in Mar. 2023 is calculated as

Revenue Per Share (A: Mar. 2023 )	=	Revenue (A: Mar. 2023 )	/	Shares Outstanding (Diluted Average) (A: Mar. 2023 )
	=	0.009	/	2.126
	=	0.00

Virax Biolabs Group's Revenue Per Share for the quarter that ended in Sep. 2023 is calculated as

Revenue Per Share (Q: Sep. 2023 )	=	Revenue (Q: Sep. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2023 )
	=	0.077	/	0.178
	=	0.43

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.44

Virax Biolabs Group (NAS:VRAX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Virax Biolabs Group Revenue per Share Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.